Drug Trial Radar · NCT03023787
Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Aug 2016
Primary completion
Dec 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of Hepalatide(L47) and characterize the clinical pharmacokinetics in healthy volunteers.
Conditions
- Hepatitis B, Chronic
Interventions
HepalatideDrug
There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
PlaceboDrug
There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Healthy participants with treatment-related adverse events as assessed by "guiding principle of grading standards for the adverse reactions in clinical trials of vaccine for prevention" or CTCAE v4.0Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
302 Military Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.